Pasar al contenido principal

NUEVAS APROXIMACIONES TERAPEUTICAS PARA EL TRATAMIENTO DE ENFERMEDADES HEREDITARIAS DE FALLO DE MEDULA OSEA

RTI2018-097125-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CENTRO DE INVESTIGACION ENERGETICA MEDIOAMBIENTAL Y TECNOLOGICA (CIEMAT)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Generation of dyskeratosis congenita-like hematopoietic stem cells through the stable inhibition of DKC1

  • Carrascoso-Rubio, C.
  • Zittersteijn, H. A.
  • Pintado-Berninches, Laura
  • Fernández-Varas, Beatriz
  • Lozano, M. L.
  • Manguan-García, Cristina
  • Sastre, Leandro
  • Bueren-Calabuig, Juan A.
  • Perona Abellón, Rosario
  • Guenechea, Guillermo
© The Author(s)., Dyskeratosis congenita (DC) is a rare telomere biology disorder, which results in different clinical manifestations, including severe bone marrow failure. To date, the only curative treatment for the bone marrow failure in DC patients is allogeneic hematopoietic stem cell transplantation. However, due to the toxicity associated to this treatment, improved therapies are recommended for DC patients. Here, we aimed at generating DC-like human hematopoietic stem cells in which the efficacy of innovative therapies could be investigated. Because X-linked DC is the most frequent form of the disease and is associated with an impaired expression of DKC1, we have generated DC-like hematopoietic stem cells based on the stable knock-down of DKC1 in human CD34+ cells with lentiviral vectors encoding for DKC1 short hairpin RNAs. At a molecular level, DKC1-interfered CD34+ cells showed a decreased expression of TERC, as well as a diminished telomerase activity and increased DNA damage, cell senescence, and apoptosis. Moreover, DKC1-interfered human CD34+ cells showed defective clonogenic ability and were incapable of repopulating the hematopoiesis of immunodeficient NSG mice. The development of DC-like hematopoietic stem cells will facilitate the understanding of the molecular and cellular basis of this inherited bone marrow failure syndrome and will serve as a platform to evaluate the efficacy of new hematopoietic therapies for DC., This work was supported by grants from the “Ministerio de Economía, Comercio y Competitividad and Fondo Europeo de Desarrollo Regional (FEDER)” (SAF2015-68073-R) and from the “Ministerio de Ciencia, Innovación y Universidades and Fondo Europeo de Desarrollo Regional (FEDER)” (RTI2018-097125-B-I00) and P17-01401 from “Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (FIS-ISCIII)”. The authors also thank the Fundación Botín for promoting translational research at the Hematopoietic Innovative Therapies Division of the CIEMAT. CIBERER is an initiative of the “Instituto de Salud Carlos III” and “FEDER”. CCR was supported by an FPI grant from the Universidad Autónoma de Madrid (UAM).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia

  • Lasaga, Miren
  • Río, Paula
  • Vilas-Zornoza, Amaia
  • Planell, Nuria
  • Navarro, Susana
  • Alignani, Diego
  • Fernández-Varas, Beatriz
  • Mouzo, Daniel
  • Zubicaray, Josune
  • Pujol, Roser M.
  • Nicoletti, Eileen
  • Schwartz, Jonathan D.
  • Sevilla Navarro, Julian
  • Ainciburi, Marina
  • UllateAgote, Asier
  • Surrallés, Jordi
  • Perona Abellón, Rosario
  • Sastre, Leandro
  • Prosper, Felipe
  • Gómez-Cabrero, David
  • Bueren, Juan
Clinical trials have shown that lentiviral-mediated gene therapy can ameliorate bone marrow failure (BMF) in nonconditioned Fanconi anemia (FA) patients resulting from the proliferative advantage of corrected FA hematopoietic stem and progenitor cells (HSPC). However, it is not yet known if gene therapy can revert affected molecular pathways in diseased HSPC. Single-cell RNA sequencing was performed in chimeric populations of corrected and uncorrected HSPC co-existing in the BM of gene therapy-treated FA patients. Our study demonstrates that gene therapy reverts the transcriptional signature of FA HSPC, which then resemble the transcriptional program of healthy donor HSPC. This includes a down-regulated expression of TGF-β and p21, typically up-regulated in FA HSPC, and upregulation of DNA damage response and telomere maintenance pathways. Our results show for the first time the potential of gene therapy to rescue defects in the HSPC transcriptional program from patients with inherited diseases; in this case, in FA characterized by BMF and cancer predisposition., This work was supported by grants from the European Commission’s Seventh Framework Program (HEALTH-F5-2012-305421) to the EUROFANCOLEN Consortium (to JB and JSe); from Ministerio de Ciencia, Innovación y Universidades and Fondo Europeo de Desarrollo Regional (RTI2018-097125-B-I00 and PID2021-125077OB-C21, to PR and SN); from Gobierno de Navarra, Departamento de Desarrollo Económico y Empresarial (AGATA 0011-1411-2020-000010); from Instituto de Salud Carlos III (ISCIII) and co-financed by FEDER CIBERONC (CB16/12/00489 and CB16/12/00225); Redes de Investigación Cooperativa (TERCEL RD16/0011/0005); “Instituto de Salud Carlos III (ISCIII)/Red Espanola de Terapias Avanzadas RICORS/TERAV” (RD21/0017/0027), supported by European Union-NextGenerationEU and from Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid (AvanCell Project; B2017/BMD3692); from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain, grant n. PI20/0335 and co-funded by European Regional Development (FEDER) funds. MA was supported by a PhD Fellowship from the Ministerio de Ciencia, Innovación y Universidades (FPU18/05488). CIBERER and CIBERONC are initiatives of the Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes

  • Sevilla, Julián|||0000-0002-6852-1860
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Río, Paula
  • Sánchez Domínguez, Rebeca
  • Zubicaray, Josune|||0000-0003-4115-9598
  • Gálvez, Eva
  • Merino, Eva
  • Sebastián, Elena
  • Azqueta, Carmen
  • Casado, José A.|||0000-0003-2479-1508
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Alberquilla, Omaira|||0000-0002-0301-8340
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Román-Rodríguez, Francisco J.
  • Giménez, Yari|||0000-0002-8936-0007
  • Larcher, Lise
  • Salgado Sánchez, Rocío Nieves|||0000-0003-1678-8982
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Hladun, Raquel|||0000-0002-3191-1750
  • Castillo, Ana
  • Soulier, Jean|||0000-0002-8734-5356
  • Querol, Sergi|||0000-0002-1105-8633
  • Fernández, Jesús
  • Schwartz, Jonathan|||0000-0002-2211-4151
  • García de Andoín, Nagore|||0000-0003-2660-2600
  • López, Ricardo
  • Català, Albert|||0000-0003-0133-1752
  • Surralles, Jordi|||0000-0002-4041-7519
  • Díaz de Heredia, Cristina|||0000-0001-8086-296X
  • Bueren, Juan|||0000-0002-3228-7013
Difficulties in the collection of hematopoietic stem and progenitor cells (HSPCs) from Fanconi anemia (FA) patients have limited the gene therapy in this disease. We have investigated (, NCT02931071) the safety and efficacy of filgrastim and plerixafor for mobilization of HSPCs and collection by leukapheresis in FA patients. Nine of eleven enrolled patients mobilized beyond the threshold level of 5 CD34 + cells/μL required to initiate apheresis. A median of 21.8 CD34 + cells/μL was reached at the peak of mobilization. Significantly, the oldest patients (15 and 16 years old) were the only ones who did not reach that threshold. A median of 4.27 million CD34 + cells/kg was collected in 2 or 3 aphereses. These numbers were markedly decreased to 1.1 million CD34 + cells/kg after immunoselection, probably because of weak expression of the CD34 antigen. However, these numbers were sufficient to facilitate the engraftment of corrected HSPCs in non-conditioned patients. No procedure-associated serious adverse events were observed. Mobilization of CD34 + cells correlated with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher proportion of CD34 + cells in bone marrow (BM). All these values offer crucial information for the enrollment of FA patients for gene therapy protocols. Mobilization and collection of HSPCs from FA patients with sufficient HSPC reserve is a safe and efficient procedure, incorporating filgrastim and plerixafor as mobilization agents. Adequate HSPC mobilization correlates with younger age, higher leukocyte counts and hemoglobin values, lower mean corpuscular volume, and higher BM CD34 + cell numbers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia

  • Casado, José A.|||0000-0003-2479-1508
  • Valeri, A.
  • Sánchez Domínguez, Rebeca
  • Vela, Paula
  • Lopez, A.
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Alberquilla, Omaira|||0000-0002-0301-8340
  • Hanenberg, H.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Segovia, J. C.
  • Minguillon, J.
  • Surralles, Jordi|||0000-0002-4041-7519
  • De Heredia, C.D.
  • Sevilla, J.
  • Rio, P.
  • Bueren, Juan|||0000-0002-3228-7013
Fanconi anemia (FA) is the most prevalent inherited bone marrow failure (BMF) syndrome. Nevertheless, the pathophysiological mechanisms of BMF in FA have not been fully elucidated. Since FA cells are defective in DNA repair, we hypothesized that FA hematopoietic stem and progenitor cells (HSPCs) might express DNA damage-associated stress molecules such as natural killer group 2 member D ligands (NKG2D-Ls). These ligands could then interact with the activating NKG2D receptor expressed in cytotoxic NK or CD8+ T cells, which may result in progressive HSPC depletion. Our results indeed demonstrated upregulated levels of NKG2D-Ls in cultured FA fibroblasts and T cells, and these levels were further exacerbated by mitomycin C or formaldehyde. Notably, a high proportion of BM CD34+ HSPCs from patients with FA also expressed increased levels of NKG2D-Ls, which correlated inversely with the percentage of CD34+ cells in BM. Remarkably, the reduced clonogenic potential characteristic of FA HSPCs was improved by blocking NKG2D-NKG2D-L interactions. Moreover, the in vivo blockage of these interactions in a BMF FA mouse model ameliorated the anemia in these animals. Our study demonstrates the involvement of NKG2D-NKG2D-L interactions in FA HSPC functionality, suggesting an unexpected role of the immune system in the progressive BMF that is characteristic of FA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia

  • Lasaga, Miren
  • Río, Paula
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Planell, Núria
  • Navarro, Susana|||0000-0002-6753-546X
  • Alignani, Diego
  • Fernández-Varas, Beatriz
  • Mouzo, Daniel
  • Zubicaray, Josune|||0000-0003-4115-9598
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Nicoletti, Eileen
  • Schwartz, Jonathan D.
  • Sevilla, Julián|||0000-0002-6852-1860
  • Ainciburi, Marina
  • Ullate-Agote, Asier|||0000-0002-8595-7703
  • Surralles, Jordi|||0000-0002-4041-7519
  • Perona, Rosario|||0000-0002-2973-5153
  • Sastre, Leandro|||0000-0003-3613-5938
  • Prosper, Felipe|||0000-0001-6115-8790
  • Gomez-Cabrero, David
  • Bueren, Juan|||0000-0002-3228-7013
Clinical trials have shown that lentiviral-mediated gene therapy can ameliorate bone marrow failure (BMF) in non-conditioned Fanconi anemia (FA) patients resulting from the proliferative advantage of corrected FA hematopoietic stem and progenitor cells (HSPC). However, it is not yet known if gene therapy can revert affected molecular pathways in diseased HSPC. Single-cell RNA sequencing was performed in chimeric populations of corrected and uncorrected HSPC co-existing in the BM of gene therapy-treated FA patients. Our study demonstrates that gene therapy reverts the transcriptional signature of FA HSPC, which then resemble the transcriptional program of healthy donor HSPC. This includes a down-regulated expression of TGF-β and p21, typically up-regulated in FA HSPC, and upregulation of DNA damage response and telomere maintenance pathways. Our results show for the first time the potential of gene therapy to rescue defects in the HSPC transcriptional program from patients with inherited diseases; in this case, in FA characterized by BMF and cancer predisposition.